Trial Profile
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2019
Price :
$35
*
At a glance
- Drugs Parsatuzumab (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NILE
- Sponsors Genentech
- 04 Dec 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 May 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov